Chinese PD Registry
Chinese PD Registry
The purpose of the Chinese Parkinson's disease Registry (CPDR) is to develop a database of
 patients with Parkinson's disease in China.
Parkinson's disease (PD) is the second most common disorder among degenerative neurological
 diseases. PD is a complicated disease which consists of different subtypes. A certain type of
 parkinsonism has its unique clinical feature and genetic basis. Standards of classification
 and prognosis in different PD subtypes are still poorly understood. Investigators aim to
 establish a database of longitudinal recruited PD cohort ,and characterize the clinical
 feature, genetic basis, environmental factors and their interactions among different PD
 subtypes in China, identify natural history of a highly-presentative Chinese PD cohort and to
 discern major milestones in the disease process which indicates disease progression.

 Data were collected at baseline, 12±1 months during the routine follow-up visits. Information
 about detailed disease history, level of education, significant chronic comorbidities,
 physical examination, medication history, family history, living habits and toxic exposure
 history, which include smoking, drinking tea, alcoholic consumption, drinking coffee,
 exposure to pesticide or occupational solvent, history of carbon monoxide poisoning and
 recurrent head trauma will be recorded at baseline. For each evaluation, the same
 questionnaires will be conducted. A standardized neurological assessment according to the
 recommendation of Consensus on the construction of clinical database of Parkinson's disease
 and movement disorders in China. The Unified Parkinson's Disease Rating Scale (UPDRS) part
 III is conducted for motor assessment, all the patients are evaluated in "OFF" state. The
 clinical stage of PD is assessed by Hoehn and Yahr scale (H-Y). The non-motor symptoms are
 evaluated by Non-motor Symptom Scale (NMSS), autonomic symptoms are evaluated by The Scale
 for outcomes in Parkinson disease for Autonomic Symptoms (SCOPA-AUT). Constipation was
 diagnosed by Functional Constipation Diagnostic Criteria Rome Ⅲ. The 39-item Parkinson's
 Disease Qestionnaire (PDQ-39) was used to assess the quality of life. Sleep quality was
 evaluated by Parkinson's Disease Sleep Scale (PDSS) and excessive daytime sleepiness by
 Epworth Sleepiness Scale (ESS). Probable rapid eye movement sleep behavior disorder (p-RBD)
 was diagnosed by rapid eye movement sleep behavior questionnaire-Hongkong (RBDQ-HK). Restless
 leg syndrome (RLS) was diagnosed with the Cambridge Hopkins Restless Leg syndrome
 questionnaire (CH-RLSq). Cognitive assessment was used the previously validated scale, Mini
 Mental State Examination (MMSE). Olfaction test was carried out by Hyposmia Rating Scale
 (HRS), a proportion of patients was also ascertained by Sniffin's Sticks. Depression was
 diagnosed by Hamilton Depression Scale (HAMD). Symptom of fatigue was measured by PD fatigue
 severity scale (PFS). Wearing-off was evaluated by WOQ-9 and freezing gait by new freezing
 gait questionnaire scores (NFOGQ). Dyskinesis was evaluated by Rush Dyskinesia Rating Scale.
 DNA samples extracted from peripheral blood and all the PD patients will be examed by Whole
 Exome Sequencing or Whole-genome sequencing. All the participants are scanned by structural
 MRI to exclude obvious intracranial lesions and other parkinsonism such as MSA, PSP and WD.
Inclusion Criteria:

 -  Patients diagnosed with PD by UK Brain Bank Diagnostic Criteria and other standard
 criteria.

 Exclusion Criteria:

 -  Lack of capacity to consent to participate in the project